Sanofi (SNY) Exercises License Extension Option to Nurix’s (NRIX) STAT6 Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- US stock futures fall as fading Iran peace prospects drive up oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Leerink Partners Reiterates Market Perform Rating on Nurix (NRIX)
June 2, 2025 11:14 AM EDTLeerink Partners analyst Faisal Khurshid reiterated a Market Perform rating and $16.00 price target on Nurix (NASDAQ: NRIX).
The analyst comments "Bottom Line: This morning NRIX announced that partner SAN FP (OP, Risinger) exercised their option to license NRIX's STAT6 program, including development candidate NX-3911. We believe NRIX's STAT6 program has been seen as an interesting... More
